
Cardiology Registrar & Clinical Research Fellow @EdinUniCVS | Coronary disease • Biomarkers • Troponin • Data visualisation • R Studio • Statistics
Edinburgh, Scotland
Joined May 2016
- Tweets173
- Following349
- Followers190
- Likes383
Pinned Tweet
Pleased to share the results of our latest study evaluating the role of "High-Sensitivity Cardiac Troponin for Risk Assessment in Chronic Coronary Disease"
Out now in @JACCJournals
authors.elsevier.com/a/1hV-L…
1/2
Ryan Wereski retweeted
Hand-held echocardiography can play an important role in patients hospitalised with acute coronary syndrome! Big thank you to all co-authors for making this happen @sjoshi_23 @russeverett3 @MikolajBuchwald @EchoSoliman @Cosyns academic.oup.com/ehjcimaging…
Ryan Wereski retweeted
In ORBITA-STAR, angina verification with an ischaemic stimulus powerfully predicted response to PCI. #EuroPCR2024
Perhaps we have been too focused on treatment when the problem always lay in the diagnosis! Published today in #JACC jacc.org/doi/10.1016/j.jacc.… @rallamee
Ryan Wereski retweeted
A new and important paper from JACC on EPA and Lp(a) from REDUCE-IT. Baseline Lp(a) was highly predictive of events in people with high TG and controlled LDL-C, and risk was linear, not threshold. EPA was a/w benefit irrespective of Lp(a) levels. Expands data to people with high TGs, and also more data that Lp(a) risk is independent of LDL-C and apoB. Now we need to wait for outcomes data on Lp(a) lowering.
jacc.org/doi/10.1016/j.jacc.…
Ryan Wereski retweeted
"What is a normal cholesterol?"
As a cardiologist, I get this question all the time.
Most people are getting this all wrong.
📕Make Sure To Bookmark✅
🧵👇
/1
Ryan Wereski retweeted
Additive antithrombotic effects of PAR4 antagonism in patients with coronary artery disease receiving single or dual antiplatelet therapies @HighSTEACS @SamuelDebono @jennynashville
ahajrnls.org/3Tg6LiZ
Ryan Wereski retweeted
If PCI as a "therapy" for stable ischemic heart disease is controversial, its role as a "prevention" for vulnerable plaques is even more controversial.
In a few weeks, at ACC.24, the PREVENT investigators will present the results of a multicenter, open-label, randomized controlled trial comparing preventive PCI plus medical therapy versus medical therapy alone in more than 1,600 patients with functionally insignificant (fractional flow reserve >0.80) vulnerable plaques containing multiple high-risk features.
Anticipating the presentation and publication of PREVENT, we invited @dukwoo_park and @DavidLBrownMD to debate on prophylactic stenting of vulnerable plaques.
eurointervention.pcronline.c…
“Biomarkers do not replace clinical judgement and we must think: What is the biomarker telling me in the setting in which it was measured” @JJheart_doc @escardio @AbbottNews – at Amsterdam, The Netherlands
9
315
“Pre-operative cardiovascular risk assessment allows patients to make an informed choice about proposed surgery” @escardio @AbbottNews – at Amsterdam, The Netherlands
“Risk prediction by machines”. Excellent presentation by @chapdoc1 at @escardio #Amsterdam – at Amsterdam, The Netherlands
Ryan Wereski retweeted
Bringing up the rear of team Edinburgh, finally en route to #ESC2023 with @RyanWereski after an honest morning’s work and an honest evening’s gin and tonic tasting 🍸
Tot snel Amsterdam and my wonderful cardiology friends 🤩 🌷 🇳🇱
@escardio @ESC_Journals – at Scotland, United Kingdom
Ryan Wereski retweeted
The goal of the STOP-CA trial was to assess whether concomitant treatment w/ atorvastatin may prevent the reduction in LVEF that may be seen in patients w/ lymphoma receiving anthracycline-based chemotherapy.
Get the trial details here ➡️ bit.ly/440Xu0n #CardioOnc
Ryan Wereski retweeted
In patients with chronic CAD, an elevated #troponin identifies those more likely to have MI or CV death. Routine troponin testing in this setting could inform patient selection for additional treatment. bit.ly/3rZhhjp
#JACC #cvCAD #CardioTwitter #cvPrev #cvMI
Ryan Wereski retweeted
Latest @JACCJournals: The Evolving Role of Cardiac Troponin: From Acute to Chronic Coronary Syndromes bit.ly/456vHNc. Our editorial addressing the research by @RyanWereski @HighSTEACS et al. on hs #troponin for risk assessment in chronic CAD bit.ly/3QjSq3W
Key findings 🔑:
- Troponin concentrations are 2⃣-times higher in patients with MACE compared to without
- MACE is 4⃣-fold higher when troponin ›99th centile compared to <5 ng/L
- A troponin concentration >10 ng/L increased likelihood of MACE by 50%
6
233
Ryan Wereski retweeted
A good opportunity to remind researchers that unadjusted Kaplan-Meier survival curves are mixtures of survival time distributions with strange weights, due to within-treatment variation of patient characteristics. #Statistics #clinicalresearch @vandy_biostat @EdgeforScholars
Friday night 🍺 after a very busy week of clinic, and wondering - why don’t we use Cox-Kalbfleisch-Prentice plots much more often and K-M rarely? These are more relevant and useful! 🤔 HT @f2harrell #rms
Ryan Wereski retweeted
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease #AHAJournals
ahajournals.org/doi/10.1161/…
Ryan Wereski retweeted
A masterpiece by @maciejbanach & colleagues of only 2-pages of which every line must be read. IF YOU FOLLOW ME - PROMISE TO READ ASAP - The paper so succinctly refutes every denier statement ever made. Free download ow.ly/tLjO50Pc8GN @nationallipid academic.oup.com/eurheartj/a…


































